Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million to gain access to the only ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development. The companies are evaluating next steps, if any ...